Portfolio

amiko AI

amiko AI is an artificial intelligence technology company focused on applications in drug discovery and precision medicine. The Company develops a platform for scientific collaboration between humans and artificial intelligence designed to support molecular research and development processes and improve data-driven decision-making processes.

The technology stack particularly includes the so-called “AI Co-Scientist,” which is used for the generation and evaluation of scientific hypotheses, including the identification of new target molecules and the repurposing of existing drugs. In addition, the platform includes the modular “ToolUniverse Hub,” which enables the execution and combination of automated workflows in molecular design, as well as the “Ontology Builder,” an ontology-based biomedical knowledge structure for the organization of data and the assurance of traceability of analytical results.

The solutions offered are primarily targeted at companies and research institutions in the biotechnology and pharmaceutical industries and address applications in early-stage drug discovery and data-driven research processes. The business model is based on the provision of software-based solutions and, prospectively, on licensing and cooperation models with industry partners.

amiko AI operates in a technologically dynamic market for AI-supported research solutions characterized by increasing data availability, growing computing capacities and the demand for more efficient research processes. The further development of the Company depends in particular on the continued technological advancement of the platform, its integration into existing research processes and market penetration within the target market.

Danner Laboratory Inc.

Danner Lab is a CLIA-certified diagnostic laboratory founded in 1991 and headquartered in San Diego, California (USA), specializing in cytological and molecular diagnostics with a focus on oncology. The Company has many years of experience in the performance of cytological examinations, particularly in the field of early cancer detection, and operates an additional location in Canada alongside its U.S. site.

The service portfolio includes cytological examinations, molecular infection tests and specialized procedures for the analysis of circulating tumor cells as part of modern liquid biopsy approaches. The focus of technological advancement is the “CTCReveal” platform, which is based on the identification and analysis of circulating tumor cells, and addresses applications in early cancer detection and disease monitoring. In addition, the Company is working on the structured digitization of diagnostic imaging data in order to standardize diagnostic processes and enable data-based evaluations.

The business model is based on the provision of specialized diagnostic services for medical institutions, laboratories and research partners and, prospectively, on the scaling of standardized diagnostic procedures through additional sites and partner structures. The current focus is on the North American market, which is characterized by strong demand for precise and early diagnostics as well as an innovation-driven competitive environment.

Danner Lab operates in a growing in-vitro diagnostics market driven by technological advances, the increasing importance of personalized medicine and the demand for early and precise disease diagnosis. The further development of the Company depends on the successful scaling of the diagnostic infrastructure, the regulatory classification of new diagnostic procedures and demand for innovative oncological diagnostic solutions.

Dr PAIN

Dr PAIN is a provider of non-surgical pain therapy and rehabilitation services with operations in Taiwan, Hong Kong and China. The Company develops and operates standardized treatment offerings that include medical diagnostics, physiotherapy and chiropractic services as well as structured training and prevention programs. The objective is to provide continuous and quality-assured care from initial diagnosis through aftercare.

Services are delivered through a hybrid operating model consisting of proprietary therapy centers, franchise locations and so-called shop-in-shop solutions at partner companies. As of the valuation date, the Company operated a total of 24 locations. The treatment approaches are based on standardized, partially data- and technology-supported diagnostic and treatment pathways that enable a high degree of reproducibility of services.

The business model is based on several revenue streams, including treatment revenues from proprietary centers, recurring income from franchise agreements and service revenues from partnerships. While proprietary centers allow for a high degree of control over quality and processes, franchise and partner structures provide a more asset-light scaling model.

The Company addresses a growing outpatient healthcare market spanning pain therapy, rehabilitation and preventive care, with increasing relevance as patients seek accessible, non-hospital-based solutions for long-term health management and quality-of-life improvement. Demand is underpinned by demographic trends, the rising prevalence of chronic diseases and increasing health awareness. The Company’s continued development is expected to be closely linked to effective location utilisation and scaling, expansion of the franchise network and consistent maintenance of uniform quality standards.

UHO Wellness Corporation

UHO Wellness is a Taiwan-based company that develops complementary healthcare solutions in the field of supportive care for cancer patients. The focus is on the “Phoenix Cancer Patient Program” (“PCPP”), a modular program combining standardized plant- and mushroom-based dietary supplements with structured care and application concepts. The applications are currently in the pilot phase.

The service offering includes dietary supplements that use natural ingredients manufactured in compliance with relevant quality and safety standards. The products are positioned as complementary healthcare solutions, and are not intended as a substitute for conventional medical therapies. Certain products are designed as vegan and halal-certified dietary supplements, and therefore address specific target group requirements in international markets.

The business model integrates direct customer engagement with strategic partnership structures, including collaborations with medical institutions, patient organisations and insurance companies. The Company plans to support international expansion through licensing arrangements and cooperation models. Its core target groups comprise patients undergoing treatment or aftercare, together with institutional partners across the healthcare sector.

UHO Wellness operates in a market environment supported by rising demand for complementary and preventive healthcare solutions. This demand reflects demographic shifts, the increasing prevalence of chronic diseases and growing interest in integrative treatment approaches. The Company’s continued development is expected to benefit from a successful transition from the pilot phase to operational business activities, appropriate regulatory positioning of its products and sustained market demand for complementary healthcare solutions.

Pathomics Health Pte Ltd.

Pathomics Health is a precision medicine and molecular diagnostics company founded in 2017 and headquartered in Singapore, with a regional focus on Southeast Asia. In addition to its headquarters in Singapore, the Company maintains operating activities in Malaysia as well as distribution and cooperation structures in other countries within the region, including the Philippines, Thailand, Indonesia and Taiwan.

The service portfolio includes diagnostic laboratory services in oncology and infectious disease diagnostics as well as genetic testing solutions, including the DNA-based “Pathgene” test for the creation of individualized health and risk profiles. The genetic analyses are based on modern sequencing technologies, and are supported by proprietary laboratory capacities as well as digital platform solutions for both the evaluation and provision of results. The Company also offers follow-up services for structured healthcare management and risk management.

The business model combines direct sales to private individuals with partner structures, particularly cooperations with insurance companies that integrate genetic testing services into their products (B2B2C model). The target group primarily includes affluent private customers as well as institutional partners in the insurance and healthcare sectors. Regionally, the focus is on high-growth Southeast Asian markets known for increasing healthcare expenditures and rising demand for personalized healthcare services.

Pathomics Health operates in a dynamic precision medicine market characterized by the increasing availability of medical data, technological advances in genome sequencing, and rising demand for individualized healthcare solutions. The further development of the Company is propelled by its expansion into additional markets, further development of diagnostic offerings and demand for personalized healthcare solutions.

Renhe Biotech (Australia) Pty. Ltd.

Renhe is a company founded in 2020, and headquartered in Australia, operating in the dietary supplements segment with a focus on “healthy aging.” The Company develops and distributes products based on nicotinamide adenine dinucleotide (NAD⁺), an endogenous coenzyme involved in cellular metabolic processes. The products are positioned as dietary supplements.

The Company’s key product is the “NAD+ PLUS” capsule product line. The product is registered in Australia as a listed therapeutic good (AUST L 451945) and is manufactured in accordance with applicable GMP standards. Marketing is conducted through partner structures.

The business model is based on the sale of standardized dietary supplements through distribution partners as well as scalable distribution formats, including bundled offerings and recurring subscription models. The focus is on the Chinese market, which is characterized by a growing and aging population as well as increasing health awareness.

Renhe operates in a growing market environment shaped by demographic developments, rising demand for preventive healthcare solutions and increasing interest in functional dietary supplements. Within this environment, products in the field of “healthy aging” and NAD⁺-based approaches are gaining increasing importance.

The Chinese dietary supplements market faces intense competition and a fragmented supplier structure. At the same time, the Asia-Pacific region is regarded as a significant growth driver for preventive healthcare solutions.

In addition, Renhe plans to develop applications in the field of animal dietary supplements, which are currently in an early stage. The market for animal dietary supplements is also experiencing rising demand for functional nutrition and preventive health solutions.

The Company’s continued development will require deeper market penetration across the target regions, effective management of product regulatory classification, a clear response to competitive dynamics in the dietary supplements market, and disciplined execution of its planned expansion into additional fields of application.